Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 3/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17281943 | 0.91 | L3MBTL3 (0.45) | L3MBTL3HPGDMEN1KMT2ARECQL | |
| SCHEMBL13621127 | 0.83 | HTT (0.44) | L3MBTL3HPGDMCHR1SMN1; SMN2KDM1A | |
| SCHEMBL21569670 | 0.79 | HPGD (0.38) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL27022583 | 0.78 | HPGD (0.44) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL27022600 | 0.78 | HPGD (0.44) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL27022598 | 0.78 | HPGD (0.44) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL21569678 | 0.78 | ALDH1A1 (0.41) | HPGDMEN1KMT2ARECQLSMN1; SMN2 | |
| SCHEMBL25143661 | 0.77 | ALDH1A1 (0.52) | HPGDRECQLSMN1; SMN2HRH3L3MBTL1 | |
| SCHEMBL17961859 | 0.76 | CHRNB2 (0.43) | L3MBTL3MCHR1KDM1AMAOAMAOB | |
| SCHEMBL17961830 | 0.76 | CHRNB2 (0.43) | L3MBTL3MCHR1KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | L3MBTL3 3781/4885HPGD 3552/4885MEN1 4487/4885 |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | L3MBTL3 3781/4885HPGD 3552/4885MEN1 4487/4885 |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | TLR9, TLR7, TLR8 | L3MBTL3 3059/4885HPGD 3971/4885MEN1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.